CATCH ME partners identify clinical risks and biomarkers that could be used to screen patients with atrial fibrillation

  • by Doreen Haase - Mon, 2019-01-07 16:22

Researchers at the University of Birmingham have found two biomarkers that could be used to identify atrial fibrillation in patients who have three ‘clinical risks’: older age, being male and a high Body Mass Index. 

In these patients the two biomarkers brain natriuretic peptide (BNP), a hormone secreted by the heart, and fibroblast growth factor-23 (FGF-23), a protein responsible for phosphate regulation, were strongly associated with atrial fibrillation.

These biomarkers would allow an easy screening of patients which is important to prevent life-threatening complications. Patients with atrial fibrillation have a higher risk of developing strokes. This can be prevented by treating patients at risk with anticoagulants.

 

For more details, see the press release of the University of Birmingham.

To read the full publication, follow the link below:

Chua et al (2018). ‘Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation’. was published on 7th Jan in the European Heart Journal.